RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers

Oncogenic alterations in the RAS-RAF-MEK-ERK pathway drive the growth of a wide spectrum of cancers. While BRAF and MEK inhibitors are efficacious against BRAF(V600E)-driven cancers, effective targeted therapies are lacking for most cancers driven by other pathway alterations, including non-V600E on...

Descripción completa

Detalles Bibliográficos
Autores principales: Nichols, Robert J., Haderk, Franziska, Stahlhut, Carlos, Schulze, Christopher J., Hemmati, Golzar, Wildes, David, Tzitzilonis, Christos, Mordec, Kasia, Marquez, Abby, Romero, Jason, Hsieh, Tientien, Zaman, Aubhishek, Olivas, Victor, McCoach, Caroline, Blakely, Collin M., Wang, Zhengping, Kiss, Gert, Koltun, Elena S., Gill, Adrian L., Singh, Mallika, Goldsmith, Mark A., Smith, Jacqueline A. M., Bivona, Trever G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6115280/
https://www.ncbi.nlm.nih.gov/pubmed/30104724
http://dx.doi.org/10.1038/s41556-018-0169-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6115280/
https://www.ncbi.nlm.nih.gov/pubmed/30104724
http://dx.doi.org/10.1038/s41556-018-0169-1

Ejemplares similares